Selected GBI Publications on Bioconjugation
Sesay M. Development, Manufacture and Preclinical evaluation and efficacy studies of a melanin IgM antibody labeled with Rhenium-188-Labeled against experimental human metastatic melanoma in nude mice. Second Annual Protein Engineering Summit. 2009.
E. Dadachova, E. Revskaya, M. Sesay, R. Howell, G. Thornton, et al., Pre-clinical development of a 188-Re labeled melanin-binding antibody for phase I clinical trial in patients with metastatic melanoma. J Nuclear Medicine. 2008; 49 (Supplement): 327P.
E. Dadachova, E. Revskaya, M. Sesay, H. Damania, R.Boucher et al., Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody with 188-Re against experimental human metastatic melanoma in nude mice. Cancer Biology and Therapy. 2008; 7(7): 1116-1127
Dadachova E, Revskaya E, Sesay MA, et al. Melanin-binding antibody radiolabeled with therapeutic radionuclide Re188 pre-clinical in vitro and in vivo development for Phase I clinical trial in patients with metastatic melanoma. Proceedings of the 6th International Symposium on the Targeted Anticancer Therapies. Bethesda, MD, USA, March 20-22,2008;
Revskaya E, Dadachova E, Sesay SA, et al. Pre-clinical development of a melanin-binding IgM antibody labeled with Re188 for Phase I clinical trial in patients with metastatic melanoma pigment. Cell Res. 2007; 20(6): 520-521.
Sesay, M.A. Monoclonal Antibody Conjugation via Chemical Modification. BioPharm International. 2003; December; 32-39.
Steve Pincus, et. al. Evaluation of Antigen based Heteropolymer (AHP) for Treatment of Systemic Lupus Erythematosus in a Non-Human Primate Model. Clinical Immunology. 2002; 105: 141-154.
E. Dadachova, A Casadevall, M. Sesay, H. Damania, and P. Smariga, Radiolabeled monoclonal antibodies using TCEP, and uses thereof. US Patent Application number 61/000,795; 2008. (Patent Pending); Also patent pending filed with World, Canada, Australia, Japan, Europe and other countries.
E. Dadachova, A Casadevall, M. Sesay, H. Damania, and P. Smariga, Disposable column system for purification of radiolabelled polypeptides. World Intellectual Property Organization Patent, 2009, Publication number WO/2009/058737, Application number PCT/US2008/081337; Also patent pending filed with US, Canada, Australia, Japan, Europe and others
Selected Publications on Bioconjugation in which GBI was mentioned
Vallabhajosula S, Kuji I, Hamacher KA, Konishi S, Kostakoglu L, Kothari PA, Milowski MI, Nanus DM, Bander NH, Goldsmith SJ. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: Prediction of 90Y-J591 radiation dosimetry based on 111In or 177LU? J Nucl Med. 2005; 46(4):634-641.
Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003; 170:1717-1721.
Selected Patents in which GBI Scientists Participated
Leslie Casey, Stanford Lihsyng Lee, Nehal Mohamed, P. James Porter, Muctarr A. Sesay, Xiaoliang Wang. Production of bispecific molecules using polyethylene glycol linkers. US20060153839, WO2004024889 A2, WO2004024889 A3, EP1539811 A2 and EP1539811 A4.
Mohamed N, Casey L, Porter J, Wang X, Sesay M, Lee L. Bispecific molecule comprising an anti-CR1 antibody cross-linked to an antigen-binding antibody fragment. Also patent pending filed with World, Canada, Australia, Japan, Europe and other countries